Drug Trial Radar · NCT03246529
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Actual
Start
Mar 23, 2018
Primary completion
Dec 22, 2020
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- BioLineRx, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
Conditions
- Multiple Myeloma
Interventions
BL-8040 1.25 mg/kg + G-CSFDrug
Up to 2 subcutaneous (SC) injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
Placebo +G-CSFDrug
Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis SessionsTime frame: From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
University of Florida
Gainesville, Florida
University of Miami
Miami, Florida
Loyola University Medical Center
Chicago, Illinois
University of Maryland
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
The Washington University School of Medicine
St Louis, Missouri
University of Cincinnati
Cincinnati, Ohio
MD Anderson Cancer Center
Houston Texas, Texas
Huntsman Cancer Institute in University of Utah
Salt Lake City, Utah
University of Koln
Cologne, Koln, Germany
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
Budapest, Hungary
University of Debrecen
Debrecen, Hungary
Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele
Catania, Italy
Presidio Ospedaliero Morelli Viale Europa
Reggio Calabria, Italy
Hospital de La Santa Creu I Sant Pau
Barcelona, Spain
Hospital University Ramon y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.